Skip to main content
Erschienen in: Breast Cancer Research 1/2018

Open Access 01.12.2018 | Correction

Correction to: Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells

verfasst von: Iain R. Hutcheson, Janice M. Knowlden, Steve E. Hiscox, Denise Barrow, Julia M. W. Gee, John F. Robertson, Ian O. Ellis, Robert I. Nicholson

Erschienen in: Breast Cancer Research | Ausgabe 1/2018

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The original article can be found online at https://​doi.​org/​10.​1186/​bcr1754

Correction

After the publication of this work [1], an error was noticed in Fig. 2b and Fig. 4b as well as Fig. 5d. and Fig. 5d. Images of the ERK1/2 blots were accidentally duplicated. In Fig. 5a. and Fig. 5c., the last lane for p-ERK1/2 was mistakenly cropped out of the final image. The original blot for Fig. 4b., “total EGFR” (or lane 2) is shown below to avoid any misunderstanding of the data. We apologize for this error, which did not affect any of the interpretations or conclusions of the article.
Fig. 4b. Uncropped original blot of “total EGFR” suggests that total EGFR levels increase with gefitinib treatment. However, increases in EGFR expression in response to gefitinib, are not seen across the study, which would suggest this increase is simply an anomaly.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
download
DOWNLOAD
print
DRUCKEN
Literatur
1.
Zurück zum Zitat Nicholson IR, et al. Heregulin β1 drives gefitinib-resistant growth, and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res. 2007;9(4):R50.CrossRefPubMedPubMedCentral Nicholson IR, et al. Heregulin β1 drives gefitinib-resistant growth, and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res. 2007;9(4):R50.CrossRefPubMedPubMedCentral
Metadaten
Titel
Correction to: Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells
verfasst von
Iain R. Hutcheson
Janice M. Knowlden
Steve E. Hiscox
Denise Barrow
Julia M. W. Gee
John F. Robertson
Ian O. Ellis
Robert I. Nicholson
Publikationsdatum
01.12.2018
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 1/2018
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-018-0999-6

Weitere Artikel der Ausgabe 1/2018

Breast Cancer Research 1/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.